Journal ArticleDOI
Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.
TLDR
An unsuspected abnormality in all cells from the nine patients with chronic myelogenous leukaemia has been detected with quinacrine fluorescence and various Giemsa staining techniques, suggesting that there may be a hitherto undetected translocation between the long arm of 22 and thelong arm of 9, producing the 9q+ chromosome.Abstract:
CELLS from nine consecutive patients with chronic myelogenous leukaemia (CML) have been analysed with quinacrine fluorescence and various Giemsa staining techniques. The Philadelphia (Ph1) chromosome in all nine patients represents a deletion of the long arm of chromosome 22 (22q−)1,2. An unsuspected abnormality in all cells from the nine patients has been detected with these new staining techniques. It consists of the addition of dully fluorescing material to the end of the long arm of one chromosome 9 (9q+). In Giemsa-stained preparations, this material appears as an additional faint terminal band in one chromosome 9. The amount of additional material is approximately equal to the amount missing from the Ph1 (22q−) chromosome, suggesting that there may be a hitherto undetected translocation between the long arm of 22 and the long arm of 9, producing the 9q+ chromosome.read more
Citations
More filters
Journal ArticleDOI
Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and migratory abilities of chronic myelogenous leukemia cells
Simona Taverna,Valeria Amodeo,Laura Saieva,Antonio Russo,Marco Giallombardo,Giacomo De Leo,Riccardo Alessandro +6 more
TL;DR: The results show that the miR-126 shuttled by exosomes is biologically active in the target cells, and support the hypothesis that exosomal miRNAs have an important role in tumor-endothelial crosstalk occurring in the bone marrow microenvironment, potentially affecting disease progression.
Journal ArticleDOI
Src Family Kinases Phosphorylate the Bcr-Abl SH3-SH2 Region and Modulate Bcr-Abl Transforming Activity
Malcolm A. Meyn,Matthew B Wilson,Fadi A. Abdi,Nathalie Fahey,Anthony P. Schiavone,Jiong Wu,James M. Hochrein,John R. Engen,Thomas E. Smithgall +8 more
TL;DR: The unexpected observation that Hck, Lyn, and Fyn strongly phosphorylate the SH3-SH2 region of Bcr-Abl is reported, which suggests that phosphorylation of the SH2-SH3 region by Src family kinases impacts Bcr -Abl protein conformation and signaling.
Book ChapterDOI
Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia
M. Stockshläder,S Hegewisch-Becker,W Krüger,Dieck At,M. Hoffknecht,Carolina Berger,B. Kohlschütter,Hans Martin,S. O. Peters,Hartmut Kabisch,R. Kuse,H. J. Weh,D. K. Hossfeld,A R Zander +13 more
TL;DR: The outcome of patients with Ph + acute lymphoblastic leukemia continues to be poor despite high-dose therapy due to high relapse rates, and the development of additional measures to enhance the antileukemic efficacy of bone marrow transplantation is necessary.
Journal ArticleDOI
Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.
Brian J. P. Huntly,François Guilhot,Alistair Reid,George S. Vassiliou,Evelin Hennig,Christina Franke,J Byrne,André Brizard,Dietger Niederwieser,Julie Freeman-Edward,Gavin Cuthbert,Nick Bown,Richard E. Clark,Elizabeth P. Nacheva,Anthony R. Green,Michael W. Deininger +15 more
TL;DR: No difference in survival is found between patients with and without deletions of the derivative chromosome 9, contrasting with previous reports in cohorts with a lower proportion of patients treated with imatinib.
Journal ArticleDOI
Chronic myeloid leukemia: a historical perspective.
TL;DR: From 1980 onwards allogeneic stem cell transplantation (SCT) became the treatment of choice for eligible patients and the era of tyrosine kinase inhibitors (TKI) began in 1998 and today the use of the original TKI, imatinib, has replaced SCT as initial therapy for patients who present with CML in chronic phase.
References
More filters
Journal ArticleDOI
New Technique for Distinguishing between Human Chromosomes
TL;DR: It seems probable, therefore, that the darker staining with Giemsa of these regions, after denaturation and annealing, indicates the presence of highly repetitive DNA.
Journal ArticleDOI
Technique for Identifying Y Chromosomes in Human Interphase Nuclei
TL;DR: This work investigated the possibility of positively identifying male nuclei in interphase by virtue of this staining property of the Y chromosome using quinacrine dihydro-chloride.
Journal ArticleDOI
Clinical Implications of Cytogenetic Variants in Chronic Myelocytic Leukemia (CML)
TL;DR: The development of other chromosomal abnormalities in Ph1 positive patients presaged the terminal stage of the disease.
Journal ArticleDOI
Philadelphia-Chromosome-Positive and -Negative Chronic Myelocytic Leukemia
TL;DR: Chromosomal studies were performed on 61 adult patients with "typical chronic myelocytic leukemia" and the Philadelphia (Ph1) chromosome was found in 43 patients, with equal sex distribution a year after diagnosis.
Related Papers (5)
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Stephen G. O'Brien,François Guilhot,Richard A. Larson,Insa Gathmann,Michele Baccarani,Francisco Cervantes,Jan J. Cornelissen,Thomas Fischer,Andreas Hochhaus,Timothy P. Hughes,Klaus Lechner,Johan Lanng Nielsen,Philippe Rousselot,Josy Reiffers,Giuseppe Saglio,John D. Shepherd,Bengt Simonsson,Alois Gratwohl,John M. Goldman,Hagop M. Kantarjian,Kerry Taylor,Gregor Verhoef,Ann E. Bolton,Renaud Capdeville,Brian J. Druker +24 more